The experimental therapy, developed in collaboration with Merck, would be unprecedented in cancer treatment, providing a personalized vaccine for each patient, depending on their specific tumors.

The trial results boosted Moderna’s actions by 140% early in the afternoon in New York, raising its market value to US$60.4 billion.

$RE $MAGMA $TRUMP 👀👀👀👀👀👀


#CryptoRally #FOMCWatch #WyomingMovesFRNTToChainlinkCCIP #USStorageStocksExtendLosses #US30YearYieldHitsHighestSince2002